Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the
“
Company” or "
Blueberries"), a
Latin American licensed producer of medicinal cannabis and
cannabis-derived products, is pleased to announce that the Company
has received approval from the Colombian Institute of Agriculture
(“ICA”) for the registration of five proprietary non-psychoactive
cannabidiol (CBD) strains with the national cultivar registry and
to commence commercial production of these strains.
The registration and approval to commence
commercial production is amongst the first to be issued in Colombia
and a major milestone for the Company. Blueberries has now
completed all regulatory requirements to commence commercial
cultivation and sales in Colombia and export to international
markets. The Company will immediately commence cultivation of
standardized medicinal-grade cannabis for oil extract.
“The registration of these first CBD-dominant
strains is a landmark achievement for Blueberries and allows us to
commence commercial production and revenue generation,” stated Dr.
Patricio Stocker, Chief Executive Officer. “Being one of the first
companies to be granted commercial production in Colombia is a
testament to the quality of our team and operations and further
positions us as a leading Latin American licensed producer of
medicinal cannabis.”
“The Blueberries team has done an outstanding
job, working diligently with the ICA during the intricate and
lengthy review process to complete the field trials, rigorous data
collection and analysis required to receive approval for commercial
registration,” stated Camilo Villalba, Chief Operating Officer.
“The approval of our proprietary strains by the ICA is further
demonstration of the extensive agricultural, biological and genetic
expertise of our scientific and medical teams.”
Blueberries is starting the process of agronomic
evaluation of an additional 10 strains and expects soon to submit
its second lot of strains for approval. Currently Blueberries has a
total of 142 proprietary registered strains available for review
and potential approval by ICA.
About the Colombian Institute of
AgricultureThe ICA is the government entity in charge of
the prevention, surveillance, and control of sanitary, biological
and chemical risks in the agricultural, fisheries, and aquaculture
sector. Its mission is to protect the health of people, animals,
and plants and ensure high-quality trade conditions.
About Blueberries Medical
Corp.Blueberries Medical is a Latin American licensed
producer of naturally grown premium quality cannabis with its
primary operations ideally located in the Bogotá Savannah of
central Colombia and operations currently being established in
Argentina. The Company is led by a specialized team with
proprietary expertise in agriculture, genetics, extraction,
medicine, pharmacology and marketing, Blueberries is fully licensed
for the cultivation, production, domestic distribution, and
international export of CBD and THC-based medical cannabis in
Colombia. Blueberries’ combination of leading scientific expertise,
agricultural advantages and distribution arrangements has
positioned the Company to become a leading international supplier
of naturally grown, processed, and standardized medicinal-grade
cannabis oil extracts and related products.
Additional information about the Company is
available at www.blueberriesmed.com. For more information, please
contact:
Camilo Villalba, Chief Operating Officer
cvillalba@blueberriesmed.comTel: +57.313.483.0131
Jessika Angarita, Pacta Relations
angarita@pactarelations.com Tel: +1 (305) 877 4710
Cautionary Note Regarding
Forward-Looking InformationThis news release contains
"forward-looking information" and "forward-looking statements"
(collectively, "forward looking statements") within the meaning of
the applicable Canadian securities legislation. All statements,
other than statements of historical fact, are forward-looking
statements and are based on expectations, estimates and projections
as at the date of this news release. Any statement that involves
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, assumptions, future events or
performance (often but not always using phrases such as “expects”,
or “does not expect”, “is expected”, “anticipates” or “does not
anticipate”, “plans”, “budget”, “scheduled”, “forecasts”,
“estimates”, “believes” or “intends” or variations of such words
and phrases or stating that certain actions, events or results
“may” or “could”, “would”, “might” or “will” be taken to occur or
be achieved) are not statements of historical fact and may be
forward-looking statements. In this news release, forward looking
statements relate, among other things, to achieving milestones in
2019 as contemplated, or at all, ability to expand distribution
networks, ability to expand and upgrade the Company’s cultivation
facilities in Colombia, internal expectations, expectations
regarding the ability of the Company to access new Latin American
and international markets, the ability to attract and retain new
customers, and future expansion plans including development of the
cultivation, production, industrialization and marketing of
cannabis for commercial and scientific purposes.
These forward-looking statements are based on
reasonable assumptions and estimates of management of the Company
at the time such statements were made. Actual future results may
differ materially as forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to
materially differ from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Such factors, among other things, include: fluctuations
in general macroeconomic conditions; fluctuations in securities
markets; expectations regarding the size of the Colombian and
international medical cannabis market and changing consumer habits;
the ability of the Company to successfully achieve its business
objectives; plans for expansion; political and social
uncertainties; inability to obtain adequate insurance to cover
risks and hazards; and the presence of laws and regulations that
may impose restrictions on cultivation, production, distribution
and sale of cannabis and cannabis related products in Colombia,
Argentina and elsewhere; and employee relations. Although the
forward-looking statements contained in this news release are based
upon what management of the Company believes, or believed at the
time, to be reasonable assumptions, the Company cannot assure
shareholders that actual results will be consistent with such
forward-looking statements, as there may be other factors that
cause results not to be as anticipated, estimated or intended.
Readers should not place undue reliance on the forward-looking
statements and information contained in this news release. The
Company assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change, except as required by law.
Additional information regarding the Company,
and other risks and uncertainties relating to the Company's
business are contained under the heading "Risk Factors" in the
Company's Listing Statement dated January 31, 2019 filed on its
issuer profile on SEDAR at www.sedar.com.
No stock exchange, securities commission or
other regulatory authority has approved or disapproved the
information contained herein.
Blueberries Medical (CSE:BBM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Blueberries Medical (CSE:BBM)
Historical Stock Chart
From Aug 2023 to Aug 2024